Treatment and pathogenesis research of Banxia Baizhu Tianma decoction on borderline hypertension

onghua Hospital affiliated to Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) Patients with borderline hypertension;
•(2) With vertigo (or headache), consistent with the wind-phlegm syndrome;
•(3) Aged from 18 to 70 years;
•(4) Fully understand the study, sign the informed consent and ensure the compliance;
•(5) If the subject has been taking hypotensive related Traditional Chinese medicine or Western medicine, the drug should be stopped for 2 weeks before inclusion.

•(1) Symptoms caused by Non-essential hypertension, diagnosed hypertension, nervous system disease, neurosis, cervical spondylosis, menopausal syndrome, etc.;
•(2) Patients with severe cardiopulmonary insufficiency, severe arrhythmia, immune system and other diseases;
•(3) Patients with allergic constitution or allergic to this test drug or patients with severe adverse reactions to this test drug;
•(4) Patients with tumors and cancers;
•(5) Manic, depression and other mental disorders;
•(6) Persons with a history of infectious diseases, such as tuberculosis, hepatitis B and HIV carriers.
•(7) Combined with poor controlled diseases such as diabetes, hyperlipidemia, respiratory infections, etc.;
•(8) A history of opioid analgesics, sedative and hypnotic drugs, and alcohol abuse;
•(9) Severe liver and kidney diseases or severe liver and kidney function impairment (ALT or AST are more than 1.5 times higher than the normal upper limit, and serum creatinine level is more than 1.5 times higher than the normal upper limit)
•(10) Patients with hematologic disorders, e.g.
•1) hemoglobin <9g/dL, or hematocrit <30%;
•2) White blood cell count <3.0x10^9/L;
•3) Neutrophils count <1.2.0x10^9/L;
•4) Platelet count <100x10^9/L, etc.;
•(11) Confirmed pregnant or suspected pregnant women, or having a pregnancy plan during the test.

发起方

onghua Hospital affiliated to Shanghai University of Traditional Chinese Medicine